XML 88 R72.htm IDEA: XBRL DOCUMENT v3.25.0.1
ACQUISITIONS AND LICENSING AGREEMENTS - Pro Forma Information (Details) - XIIDRA® and Certain Other Ophthalmology Assets Acquisition - Bausch + Lomb - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Business Acquisition [Line Items]    
Revenues $ 9,006 $ 8,611
Net loss (822) (507)
Net loss attributable to Bausch Health Companies Inc. $ (762) $ (498)